Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04364789 · ClinicalTrials.gov registry record · Phase 1
Phase I, First-In-Human Study of TT-00920 in Healthy Subjects
A Phase 1 study, sponsored by TransThera Sciences (Nanjing).
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT04364789: Completed Phase 1 study, sponsored by TransThera Sciences (Nanjing).
NCT04364789 is a Phase 1 study that has completed, run by TransThera Sciences (Nanjing). The registered enrollment target is 42 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04364789, a Phase 1 study, has completed, sponsored by TransThera Sciences (Nanjing).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This is a first-in-human, randomized, double-blind, placebo-controlled study. The primary objectives of the study were to investigate the safety and tolerability and determine the PK profiles of single ascending doses (SAD) of TT-00920 administered to healthy subjects. The secondary objectives of the study were to assess the effect of food on the PK of TT-00920 following an oral dose.
Primary Outcome
Safety and tolerability of TT-00920
Interventions
- DRUG Placebos
- DRUG TT-00920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2022-03-17 |
| Phase | Phase 1 |
What the finished NCT04364789 record still lists
NCT04364789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04364789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04364789 about?
NCT04364789 is a clinical study titled "Phase I, First-In-Human Study of TT-00920 in Healthy Subjects". This is a first-in-human, randomized, double-blind, placebo-controlled study. The primary objectives of the study were to investigate the safety and tolerability and determine the PK profiles of single ascending doses (SAD) of TT-00920 administered to healthy subjects. The secondary objectives of th...
What is the current status of trial NCT04364789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2020-02-05. Estimated completion is 2022-03-17.
What interventions are being tested in trial NCT04364789?
The interventions under investigation include: Placebos (DRUG), TT-00920 (DRUG).
Who is sponsoring clinical trial NCT04364789?
This trial is sponsored by TransThera Sciences (Nanjing), which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04364789's enrollment target sits among peer trials
42 1105th of 2000 higher than 876 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI